Lamivudine/Zidovudine Mylan (Zidovudine, Lamivudine)

Lamivudine/Zidovudine is a nucleoside reverse transcriptase inhibitor used in the management of HIV infection.

• Adults with HIV‑1 infection: reduces viral replication, increases CD4+ cell counts, and improves clinical outcomes when used in combination therapy.
• Children with HIV‑1 infection: helps control viral load, supports immune system development, and is incorporated into pediatric antiretroviral regimens.
• Pregnant women with HIV‑1 infection: may be prescribed to reduce mother‑to‑child transmission as part of a supervised treatment plan.
• Patients co‑infected with hepatitis B: lamivudine component provides activity against HBV, offering dual antiviral benefit.

• Lamivudine and zidovudine are nucleoside analogues that are phosphorylated intracellularly to their active triphosphate forms. These active metabolites compete with natural nucleosides for incorporation into the viral DNA by HIV reverse transcriptase. Incorporation results in premature chain termination, halting synthesis of proviral DNA and thereby suppressing viral replication. The combined effect of both agents enhances potency and reduces the emergence of resistance.

Lamivudine/Zidovudine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset, often transient.
• Headache: occasional tension‑type headache.
• Fatigue: general tiredness, especially during treatment initiation.
• Diarrhea: loose stools that may improve with continued therapy.

Serious or Rare Side Effects

• Anemia: reduction in red blood cells requiring monitoring.
• Neutropenia: lowered white blood cell count increasing infection risk.
• Lactic acidosis: rare metabolic disturbance presenting with rapid breathing and abdominal pain.

When prescribing Lamivudine/Zidovudine, clinicians should observe several safety measures.

• Monitor blood counts: regular CBC testing to detect anemia or neutropenia.
• Assess liver function: periodic liver enzyme tests recommended.
• Avoid use in patients with known hypersensitivity: discontinue if allergic reaction occurs.
• Use with caution in patients with pre‑existing anemia: dose adjustment may be required.
• Pregnancy and breastfeeding: risk unknown, discuss with specialist before initiating therapy.
• Store at room temperature: keep in original container, protect from moisture and heat.

Lamivudine/Zidovudine can interact with other medicines, necessitating careful review of a patient’s regimen.

Major Interactions (Avoid)

• Didanosine: increased risk of pancreatitis.
• Zalcitabine: additive toxicity leading to peripheral neuropathy.
• Stavudine: heightened mitochondrial toxicity, may exacerbate lactic acidosis.

Moderate Interactions (Monitor Closely)

• Other NRTIs: additive bone‑marrow suppression, monitor CBC.
• Protease inhibitors (e.g., ritonavir): may increase zidovudine plasma levels.
• Non‑nucleoside reverse transcriptase inhibitors (e.g., efavirenz): may reduce efficacy of lamivudine.